Zeynep Eroglu

Zeynep Eroglu

UNVERIFIED PROFILE

Are you Zeynep Eroglu?   Register this Author

Register author
Zeynep Eroglu

Zeynep Eroglu

Publications by authors named "Zeynep Eroglu"

Are you Zeynep Eroglu?   Register this Author

49Publications

3597Reads

50Profile Views

An evaluation of encorafenib for the treatment of melanoma.

Expert Opin Pharmacother 2020 Feb 30;21(2):155-161. Epub 2019 Nov 30.

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1694664DOI Listing
February 2020

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Semin Cancer Biol 2019 Nov 2. Epub 2019 Nov 2.

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, United States; Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2019.10.017DOI Listing
November 2019

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

EBioMedicine 2019 Oct 5;48:178-190. Epub 2019 Oct 5.

The Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.09.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838387PMC
October 2019

The emergence of neoadjuvant therapy in advanced melanoma.

Melanoma Manag 2019 Oct 18;6(3):MMT27. Epub 2019 Oct 18.

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2019-0007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891937PMC
October 2019

Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.

Expert Opin Drug Saf 2019 05 24;18(5):381-392. Epub 2019 Apr 24.

a Department of Cutaneous Oncology , Moffitt Cancer Center , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2019.1607289DOI Listing
May 2019

Effect of topical ozonetherapy on gingival wound healing in pigs: histological and immuno-histochemical analysis.

J Appl Oral Sci 2018 Dec 10;27:e20180015. Epub 2018 Dec 10.

Gazi University, Faculty of Dentistry, Department of Oral Pathology, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1678-7757-2018-0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296287PMC
December 2018

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.

Onco Targets Ther 2018 14;11:9081-9089. Epub 2018 Dec 14.

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S171693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299465PMC
December 2018

Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma.

Expert Opin Orphan Drugs 2018 28;6(9):545-551. Epub 2018 Aug 28.

The Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, 10920 McKinley Dr, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678707.2018.1512402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296476PMC
August 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

J Immunother Cancer 2016 18;4:60. Epub 2016 Oct 18.

Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce Ave., Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0166-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899PMC
February 2018

Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines.

Mol Cancer Ther 2018 01 13;17(1):73-83. Epub 2017 Nov 13.

The Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752595PMC
January 2018

Improving clinical outcomes with pembrolizumab in patients with advanced melanoma.

Chin Clin Oncol 2017 02;6(1)

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.01.04DOI Listing
February 2017

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.

J Immunother Cancer 2016 20;4:85. Epub 2016 Dec 20.

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612-9416 USA ; New York University Langone Medical Center, New York, NY USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0194-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170897PMC
December 2016

Improving patient outcomes to targeted therapies in melanoma.

Expert Rev Anticancer Ther 2016 Jun 12;16(6):633-41. Epub 2016 May 12.

a The Department of Cutaneous Oncology , The Moffitt Cancer Center & Research Institute , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2016.1178575DOI Listing
June 2016

Combination Therapies for Melanoma: A New Standard of Care?

Am J Clin Dermatol 2016 Apr;17(2):99-105

The Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-016-0174-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805442PMC
April 2016

Steady, dynamic, creep/recovery, and textural properties of yoghurt/molasses blends: Temperature sweep tests and applicability of Cox-Merz rule.

Food Sci Technol Int 2016 Jan 22;22(1):31-46. Epub 2015 Jan 22.

Erciyes University, Engineering Faculty, Food Engineering Department, Kayseri, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1082013214566478DOI Listing
January 2016

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.

Ther Adv Med Oncol 2016 Jan;8(1):48-56

Department of Medicine, Division of Hematology-Oncology, UCLA, 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834015616934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699264PMC
January 2016

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eur J Cancer 2015 Nov 10;51(17):2689-97. Epub 2015 Sep 10.

Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821004PMC
November 2015

Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Oncologist 2014 Feb 16;19(2):135-50. Epub 2014 Jan 16.

City of Hope Comprehensive Cancer Center, Duarte, California, USA; Harbor-UCLA Medical Center, Torrance, California, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2013-0283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926785PMC
February 2014

Role of SMC1 in overcoming drug resistance in triple negative breast cancer.

PLoS One 2013 22;8(5):e64338. Epub 2013 May 22.

Department of Diabetes, Endocrinology and Metabolic Diseases, City of Hope Comprehensive Cancer Center, Duarte, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0064338PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661439PMC
January 2014

Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib.

J Thorac Oncol 2014 Jan;9(1):e4-6

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a4700dDOI Listing
January 2014

Analysis of circulating tumor cells in breast cancer.

J Natl Compr Canc Netw 2013 Aug;11(8):977-85

From Departments of aMedical Oncology and Therapeutic Research and bHematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, California.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159355PMC
http://dx.doi.org/10.6004/jnccn.2013.0118DOI Listing
August 2013

Targeting angiopoietin-2 signaling in cancer therapy.

Expert Opin Investig Drugs 2013 Jul 27;22(7):813-25. Epub 2013 Apr 27.

City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2013.793306DOI Listing
July 2013

A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.

Cancer Chemother Pharmacol 2013 Jul 1;72(1):263-7. Epub 2013 May 1.

Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2178-xDOI Listing
July 2013

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma.

Cancer Chemother Pharmacol 2011 Oct 19;68(4):1081-7. Epub 2011 Jul 19.

Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1703-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180631PMC
October 2011